Filana Therapeutics Inc. (FLNA)
NASDAQ: FLNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FLNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $32.26M
- EPS (TTM)
- -$0.87
- Dividend yield
- None
- Ex-dividend date
- Dec 13, 2012
- 52-week range
- 0.39 – 3.45
- Day range
- 0.5898 – 0.6528
- Volume / Avg
- 1.32M / 2.09M
- Beta
- —
- Shares outstanding
- 50.30M
52-week range
FLNA stock today
Shares of Filana Therapeutics (FLNA) finished higher on Nov 20 at $0.6413, a gain of 14.52% or $0.0813 per share, versus the S&P 500's 3.70% decline. Shares are 81.4% below their 52-week high of $3.45, set on Nov 26, 2025 and 64.4% above the 52-week low of $0.39, near the bottom of the past year's range. FLNA is down 67.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.7%.
Filana Therapeutics has posted a net loss over the last twelve months (EPS of -$0.87), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Filana Therapeutics
Company profileFilana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard Jon Barry
- Headquarters
- Austin, TX
- Employees
- 17
- Website
- filanatx.com
Financial highlights
Full financialsFilana Therapeutics reported a net loss of $91.0 million, compared with a loss of $24.3 million a year earlier. Diluted earnings per share came in at -$1.88.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-90.97M | $-24.34M | $-97.22M | $-76.25M | $-32.38M |
| EPS (diluted) | $-1.88 | $-1.46 | $-2.32 | $-1.90 | $-0.82 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$6.50+913.57%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.22 vs —
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $5.25
- Ex-dividend date
- Dec 13, 2012
FLNA news
All FLNA newsFilana Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GRDXGridAI Technologies Corp. | 3.16 | -8.41% | $32.44M | vs FLNA |
| HYFTMindWalk Holdings Corp. | 0.6844 | -14.27% | $32.56M | vs FLNA |
| ATNMActinium Pharmaceuticals Inc. (Delaware) | 1.05 | -1.87% | $33.01M | vs FLNA |
| VERUVeru Inc. | 1.94 | -8.06% | $33.08M | vs FLNA |
| CUECue Biopharma Inc. | 4.15 | -7.78% | $34.69M | vs FLNA |
| SERSerina Therapeutics Inc. | 1.12 | -6.67% | $29.76M | vs FLNA |
| NXTCNextCure Inc. | 6.45 | -4.87% | $29.53M | vs FLNA |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs FLNA |
Indexes, lists and sector
Filana Therapeutics stock FAQ
What is Filana Therapeutics's stock price today?
FLNA last traded at $0.6413 as of Nov 20, 4:00 PM EST, up 14.52% on the day. Prices are delayed at least 15 minutes.
Does Filana Therapeutics pay a dividend?
Yes. Filana Therapeutics pays $0.00 per share annually. The most recent dividend of $5.25 had an ex-dividend date of Dec 13, 2012.
Who is Filana Therapeutics's CEO?
Mr. Richard Jon Barry is the chief executive officer of Filana Therapeutics Inc., which has about 17 employees.
Has FLNA ever split its stock?
Yes. The most recent FLNA stock split was a 1-for-7 split on May 10, 2017.
What is the FLNA 52-week high?
The 52-week high for FLNA is $3.45 and the 52-week low is $0.39. The stock is currently 81.4% below its high.